The purpose of this study is to see at what doses of etentamig combined with Iberdomide is better tolerated and safe for patients with relapsed/refractory multiple myeloma.

We want to see if people with breast cancer that has spread to other parts of the body can join and benefit from a 16-week exercise program at Get Real and Heel.

Do you have leukemia, lymphoma, MDS, or MF and are preparing for a stem cell transplant from an unrelated donor? If so, you might be eligible to take part in a study that will look look at combinations of medicines given after a stem cell transplant and see how well the combinations work to prevent graft versus host disease and infection.

Do you have metastatic HER2-positive breast cancer? if so you may be able to participate in this research study to find out whether zanidatamab combined with chemotherapy of study doctor's choice is safe and improves on the clinical benefit when compared to trastuzumab in combination with chemotherapy of study doctor's choice in treating the type of breast cancer you have.

We are looking for ways to help people with certain types of cancer that spread and become very serious. SolveTx has created a new treatment to target these cancers. If you join, you will have some check-ups before and after the treatment and get the study treatment. We'll make sure to keep an eye on how you're doing for about 3 years after your treatment finishes.

The purpose of this study is to test if BGB-16673 and pirtobrutinib are safe and test how well BGB-16673 compares to pirtobrutinib in participants with previously treated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL).

If you have Leukemia and are looking for an alternative treatment, you may be eligible to participate in a research study testing a new drug called AUTX-007.

Are you 18 years of age and younger than 75 years old? Do you or do you know someone with Peripheral T-cell Lymphoma? Would you be interested in using your own stem cells versus only using chemotherapy infusions? If you have large cell lymphoma (ALCL) ALK-negative, this study may interest you.

To evaluate the anti-tumor activity of carboplatin + MIRV in newly diagnosed subjects with advanced-stage (≥ 75%, ≥ 2+) serous EOC as measured by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 imaging response.

In this study, we want to look at how the drug tirzepatide works in patients with endometrial cancer compared to the standard of care treatment. We will be looking at its effect on the progression of the tumor.